160893-04-9

Basic information

• Product Name: 5-METHOXYQUINOLIN-2(1H)-ONE
• Synonyms: 5-METHOXYQUINOLIN-2(1H)-ONE
• CAS NO: 160893-04-9
• Molecular Formula: C₁₀H₉NO₂
• Molecular Weight: 175.186
• Mol File: 160893-04-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 5-METHOXYQUINOLIN-2(1H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXYQUINOLIN-2(1H)-ONE(160893-04-9)
• EPA Substance Registry System: 5-METHOXYQUINOLIN-2(1H)-ONE(160893-04-9)

Safety Data

• Hazardous Substances Data: 160893-04-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-METHOXYQUINOLIN-2(1H)-ONE is used as a therapeutic agent for its antimalarial properties, targeting the Plasmodium parasites responsible for malaria. Its antiproliferative effects also make it a candidate for the treatment of various proliferative disorders and potentially as an anticancer agent.
Used in Antimicrobial Applications:
5-METHOXYQUINOLIN-2(1H)-ONE is utilized as an antimicrobial agent, effective against a range of bacteria and other pathogens. Its ability to inhibit microbial growth can be applied in the development of new antibiotics or as a component in disinfectants and sanitizers.
Used in Antioxidant Formulations:
As an antioxidant, 5-METHOXYQUINOLIN-2(1H)-ONE is used to protect cells from oxidative damage, which can be beneficial in the formulation of health supplements and skincare products. Its antioxidant properties may also contribute to its therapeutic effects in various diseases where oxidative stress plays a role.
Used in Research and Development:
5-METHOXYQUINOLIN-2(1H)-ONE serves as a key compound in scientific research, particularly in the fields of medicinal chemistry and pharmacology. It is used to investigate the structure-activity relationships of quinoline-based drugs and to develop new therapeutic agents with improved efficacy and safety profiles.

Upstream product

• 186581-53-3 diazomethane 
• 31570-97-5 5-hydroxyquinolin-2(1H)-one 
• 67-56-1 methanol 
• 6931-19-7 5-methoxyquinoline 
• 90924-16-6 5--methoxyquinoline N--oxide 
• 578-67-6 quinolin-5-ol 
• 607-34-1 5-nitroquinoline 
• 611-34-7 5-Aminoquinoline 
• 30557-06-3 3,4-dihydro-5-methoxy-2(1H)-quinolinone 
• 56619-93-3 N-(3-methoxyphenyl)pivalamide 
• 536-90-3 m-Anisidine 
• 82673-65-2 N-(2-formyl-3-methoxyphenyl)pivalamide 
• 326479-53-2 N-(3-methoxy-phenyl)-3-phenylsulfanyl-acrylamide 
• 160893-07-2 2-chloro-5-methoxyquinoline 

Downstream Products

• 188668-80-6 5-Methoxy-1-(p-tolyl)-1,2-dihydroquinolin-2-one 
• 160893-07-2 2-chloro-5-methoxyquinoline 
• 188668-90-8 5-Hydroxy-1-(p-tolyl)-1,2-dihydroquinolin-2-one 

Relevant articles and documents

Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives

Abstract New 2-amido and ureido quinoline derivatives substituted with 2-N-methylamido-pyridin-4-yloxy group at the 5-position of quinoline (18 final compounds) have been designed and synthesized as anticancer sorafenib congeners. Among the synthesized de

2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAFV600E/C-RAF kinase inhibitory effects: Design, synthesis, in vitro cell-based and oncogenic kinase assessments

Prompted by the urgent demand for identification of new anticancer agents with improved potency and efficacy, a new series of arylamides incorporating the privileged 2-anilinoquinoline scaffold has been designed, synthesized, and biologically assessed. Ai

Preparation method and application of substituted quinoline-2(1H)-one compound

The invention belongs to the field of pharmaceutical chemistry and chemical synthesis, and concretely relates to a preparation method of a substituted quinoline-2(1H)-one compound. The invention provides a preparation method of the substituted quinoline-2(1H)-one compound. The preparation method performs an oxidation reaction on a compound represented by a formula I and an oxidant in a solvent toobtain a compound represented by a formula II. The preparation method has the advantages of simple method, high yield and low cost and is suitable for industrial production. The substituted quinoline-2(1H)-one represented by the formula II is an important intermediate of a variety of pharmaceutical active ingredients.

Palladium-catalyzed synthesis of quinolin-2(1: H)-ones: the unexpected reactivity of azodicarboxylate

Quinolin-2(1H)-one is a useful structure unit present in a wide range of natural products and pharmaceuticals. A Pd(ii)-catalyzed synthesis of quinolin-2(1H)-ones from quinoline N-oxides was developed with azodicarboxylates which act as both the activating agent and oxidant. The reaction proceeded under mild conditions and no protection against air and moisture was needed.

A nitrogen oxide C2 - bit hydroxylated method (by machine translation)

The present invention relates to nitrogen oxide C2 - bit hydroxylated method, in particular under reflux conditions in dichloroethane, three pyrrole alkyl bromide (PyBrop) [...] phosphate, sodium acetate, water and nitrogen oxides produced by the reaction of hydroxyl-substituted product. The process has simple operation, mild condition, high reaction selectivity, substrate wide applicability, high yield and the like. The application for the first time using this method to synthesize a series of 2 - hydroxyquinoline, 2 - hydroxy pyridine and 1 - hydroxy isoquinoline compound, in the establishment of the compounds of the library synthesis application have broad prospects. (by machine translation)

NOVEL QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCER CONTAINING THE SAME

The present invention refers to an excellent cancer antiproliferative potency relative to the quinoline compounds, a pharmaceutically acceptable salt, or hydrate and, number of active ingredient containing bath method and pharmaceutical composition for the prevention or treatment of cancer disease relates to search, said present invention according to compound, a pharmaceutically acceptable salt thereof, or hydrate number and number and mutant kinase protein kinase activity number of excellent cancer billion billion number activity and thus, new anticancer number is useful as the effective component can be. (by machine translation)

QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS

The present invention provides compounds of formula (I) as described herein and pharmaceutically acceptable salts, hydrates and solvates thereof for use in medicine, for example in the treatment of acute myeloid leukaemia:

Synthesis of methoxy-2-quinolones via Pummerer-type cyclization of N-aryl-N-methyl-3-(phenylsulfinyl)propionamides

The thionium ions 10 generated by Pummerer reaction of N-aryl-N-methyl-3-(phenylsulfinyl)propionamides 4 caused not only an electrophilic cyclization reaction producing 2-quinolones 8, but also the formation of the vinyl sulfides 5 and 6 in favor of the l

3,4-Dihydro-2(1H)-quinolinone as a novel antidepressant drug: Synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives

To develop a novel antidepressant drug with central nervous system- stimulating activity, we prepared a series of 1-[ω-(4-substituted phenyl-1- piperazinyl)alkyl]-3,4-dihydro-2(1H)-quinolinone derivatives and examined their activities by their effects at 30 and 100 mg/kg po on the sleeping time of mice anesthetized with halothane and on the time required for recovery from coma induced in mice by cerebral concussion. We examined their binding affinities for receptors by evaluating their ability to inhibit [3H]-1,3- di(o-tolyl)guanidine ([3H]DTG) binding to the rat whole brain membrane in comparison with three putative σ receptor agonists: 1,3-di(o-tolyl)guanidine (DTG, 66), (+)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(2-propenyl)-2,6- methano-3-benzazecin-8-ol (SKF10,047, 67), and (+)-1,2,3,4,5,6-hexahydro- 6,11-dimethyl-3(3-methyl-2-butenyl)-2,6-methano-3-benzazecin-8-ol (pentazocine, 68). Among the series of derivatives, 1-[3-[4-(3-chlorophenyl)- 1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone hydrochloride (34b) and its mesylate (34c), at a dose of 30 mg/kg po, reduced the sleeping time and the time for recovery from coma and they inhibited [3H]DTG binding for σ receptors. The putative σ receptor agonists reduced the sleeping time and the time for recovery from coma whereas two σ receptor antagonists, α- (4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol hydrochloride (BMY14802, 69) and cis-9-[3-(3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride (rimcazole, 70), were inactive in the two tests. Preadministration of the putative σ receptor antagonists 69 (3 mg/kg po) and 70 (30 mg/kg po) completely antagonized the actions of 34b and the σ receptor agonists in the test for recovery from coma. These results suggested that 34b and 34c are σ receptor agonists. Furthermore, a single administration of 1 and 10 mg/kg po 34b and 34c showed antidepressant-like activity by reducing the immobility time in the forced-swimming test with mice, while a tricyclic antidepressant, 10,11-dihydro-N,N-dimethyl-5H- dibenz[b,f]azepine-5-propanamine hydrochloride (imipramine, 1) (10 and 30 mg/kg po), did not reduce the time after a single administration. 1 reduced the time after repeated administration of 30 mg/kg po once a day for 4 days. The structure-activity relationship of the series of compounds is also discussed.

SYNTHESIS OF 5-METHOXY-2(1H)-QUINOLINONE

Methylation of 5-hydroxy-2(1H)quinolinone (1) is studied.The previous protection of the amide group in 1 is proposed as the more convenient method to obtain 5-methoxy-2(1H)-quinolinone (1a).